The estimated Net Worth of David R Guyer is at least $4.51 Million dollars as of 12 July 2024. David Guyer owns over 11,625 units of IVERIC bio Inc stock worth over $73,908 and over the last 9 years he sold ISEE stock worth over $2,627,618. In addition, he makes $1,809,580 as Executive Chairman of the Board at IVERIC bio Inc.
Sign up
David Guyer ISEE stock SEC Form 4 insiders trading
David has made over 18 trades of the IVERIC bio Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 11,625 units of ISEE stock worth $116,948 on 12 July 2024.
The largest trade he's ever made was exercising 30,060 units of IVERIC bio Inc stock on 1 June 2016 worth over $301,502. On average, David trades about 7,871 units every 82 days since 2016. As of 12 July 2024 he still owns at least 1,850 units of IVERIC bio Inc stock.
You can see the complete history of David Guyer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Guyer biography
Dr. David R. Guyer M.D. serves as Executive Chairman of the Board of the Company. He is a co-founder of our company and beginning in July 2017, serves as our executive chairman. Dr Guyer has served as chairman of our board of directors since our inception in January 2007, and previously served as our chief executive officer from April 2013 through June 2017. Prior thereto, Dr. Guyer served as a partner at SV Life Sciences Advisers, LLC, a venture capital firm, from 2009 to 2013, and as a venture partner at SV Life Sciences from 2006 to 2009. In April 2013, Dr. Guyer resumed his role as venture partner at SV Life Sciences, a role in which he served until 2016. He currently serves on the board of directors of EyePoint Pharmaceuticals, Inc. and Oxurion NV (formerly ThromboGenics NV), and previously served on the board of directors of Applied Genetic Technologies Corporation, all of which are publicly traded biotechnology or biopharmaceutical companies. Dr. Guyer co-founded Eyetech Pharmaceuticals Inc. and served as its chief executive officer and as a member of its board of directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a professor and served as chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Eye Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. Guyer is qualified to serve on our board of directors because of his extensive executive leadership experience, his extensive experience in ophthalmology, his extensive experience in the life sciences industry as an entrepreneur and venture capital investor, and his service on our board of directors and the board of directors of other life sciences companies.
What is the salary of David Guyer?
As the Executive Chairman of the Board of IVERIC bio Inc, the total compensation of David Guyer at IVERIC bio Inc is $1,809,580. There are 1 executives at IVERIC bio Inc getting paid more, with Glenn Sblendorio having the highest compensation of $2,462,150.
How old is David Guyer?
David Guyer is 60, he's been the Executive Chairman of the Board of IVERIC bio Inc since 2017. There are 4 older and 9 younger executives at IVERIC bio Inc. The oldest executive at IVERIC bio Inc is Calvin Roberts, 67, who is the Independent Director.
What's David Guyer's mailing address?
David's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Insiders trading at IVERIC bio Inc
Over the last 6 years, insiders at IVERIC bio Inc have traded over $8,677,595 worth of IVERIC bio Inc stock and bought 130,569 units worth $624,325 . The most active insiders traders include Glenn Sblendorio, Venture Capital Iv, L.P.Ver..., and Keith Westby. On average, IVERIC bio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $848,338. The most recent stock trade was executed by Keith Westby on 3 July 2023, trading 20,000 units of ISEE stock currently worth $58,800.
What does IVERIC bio Inc do?
we are a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (amd).
What does IVERIC bio Inc's logo look like?
Complete history of David Guyer stock trades at EyePoint Pharmaceuticals Inc and IVERIC bio Inc
IVERIC bio Inc executives and stock owners
IVERIC bio Inc executives and other stock owners filed with the SEC include:
-
Glenn Sblendorio,
President, Chief Executive Officer, Director -
David Guyer,
Executive Chairman of the Board -
Anthony S. Gibney,
Exec. VP and Chief Bus. & Strategy Officer -
David Carroll,
Chief Financial Officer, Senior Vice President, Treasurer -
Keith Westby,
Chief Operating Officer, Senior Vice President -
Glenn P. Sblendorio M.B.A.,
CEO & Director -
Dr. Pravin U. Dugel M.D.,
Pres -
David F. Carroll M.B.A.,
Sr. VP, CFO & Treasurer -
Christopher Paul Simms,
Sr. VP & Chief Commercial Officer -
David F. Carroll,
Sr. VP, CFO & Treasurer -
Keith Westby M.B.A.,
Sr. VP & COO -
Calvin Roberts,
Independent Director -
Jane Henderson,
Independent Director -
Adrienne Graves,
Lead Independent Director -
Axel Bolte,
Independent Director -
Kathy Galante,
Vice President, Investor Relations and Corporate Communications -
Mark Blumenkranz,
Director -
Abraham Scaria,
Chief Scientific Officer -
Evelyn Harrison,
Sr. VP & Chief Clinical Operations Officer -
Amy R. Sheehan,
Sr. VP & Chief HR Officer -
Todd D.C. Anderman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Xiao-Ping Dai Ph.D.,
Chief Technical Officer -
Dr. Samir C. Patel,
Co-Founder and Consultant -
Christopher Paul Simms,
SVP, Chief Commercial Officer -
Christine Ann Miller,
Director -
David E Redlick,
Director -
Venture Capital Iv, L.P.Ver...,
-
Anthony S Gibney,
EVP, Chief Business Officer -
Pravin Dugel,
President